NP 213

Drug Profile

NP 213

Alternative Names: Novexatin; NP-213; NVXT; NVXT Solution

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator NovaBiotics
  • Developer NovaBiotics; Taro Pharmaceutical Industries
  • Class Antifungals; Peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis

Most Recent Events

  • 01 Jan 2016 Taro Pharmaceuticals completes a phase II trial in Onychomycosis in USA (Topical) (NCT02343627)
  • 02 Nov 2015 Taro Pharmaceuticals completes enrolment in a phase II trial for Onychomycosis in USA (NCT02343627)
  • 08 Jun 2015 Phase-II development is ongoing in the UK and the US.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top